Fosun MedTech and Leo Cancer Care Collaborate to Promote a New Paradigm of Upright Particle Therapy

On November 6, 2025, at the 8th China International Import Expo (CIIE), Fosun MedTech and global radiotherapy innovation company Leo Cancer Care had a signing ceremony to celebrate the strategic partnership between two parties.

The two parties will carry out collaboration on the commercialization of the “Marie® Upright Particle Therapy Solution” in China, jointly promoting the application of the innovative upright treatment in proton, heavy-ion and other particle radiotherapy technologies, bringing more efficient new treatment options to cancer patients in China.

This cooperation not only marks a key step forward for the world’s cutting-edge upright particle radiotherapy technology in China market, but also demonstrates Fosun MedTech ’s continued commitment in the field of precision oncology, empowering the “Healthy China 2030” initiative through technological innovation.

The signing ceremony was attended by Mr. Liu Yi, the CEO and President of Fosun Pharma, Mr. Stephen Towe, the CEO of Leo Cancer Care, and other senior executives from both sides, who jointly witnessed the commencement of the cooperation.

Innovative Technology Leading the Future of Radiotherapy: The Marie® Upright Particle Therapy Solution

Developed by Leo Cancer Care, the Marie® system is the world’s leading upright particle therapy treatment room solution.

The system will innovatively enable patients to receive proton, heavy-ion, and other particle radiotherapy in an upright position, global research indicates the potential to reduce internal organ displacement caused by postural changes or respiration, with an aim to increase treatment precision.

At the same time, Marie® adopts a compact spatial design, greatly reducing the construction cycle and space requirements faced by traditional proton and heavy-ion particle therapy centers using conventional systems. This makes advanced particle radiotherapy technology easier to deploy, helping hospitals improve construction and operational efficiency, and creating a truly patient-centered, high-efficiency new model of radiotherapy.

At present, the Marie® system has been procured by several leading medical institutions in the United States and Europe, where preparations for first in the world treatments are taking place.

Strategic Consensus: Jointly Promoting the Localization of Innovative Radiotherapy Technologies in China

At the signing ceremony, Liu Yi, the Chief Executive Officer and President of Fosun Pharma, the Chairman and Chief Executive Officer of the Fosun MedTech Division, said:

“Fosun MedTech has always been committed to integrating the world’s leading medical technologies with China’s clinical needs, driving high-quality innovation in China’s healthcare industry. This cooperation with Leo marks an important milestone for Fosun MedTech in the field of precision radiotherapy. In the future, we will not only promote the implementation of the Marie® system, but also continue to introduce innovations, so that high-quality and efficient treatment solutions can reach more patients in China.”

Stephen Towe, CEO of Leo Cancer Care, said:

“We are honored to partner with Fosun MedTech to launch the Marie® system into the China market. This is not only the introduction of a technology, but also the resonance of a shared vision. Through this innovative paradigm of upright particle radiotherapy, we hope to bring better access to care and more comfortable treatment experiences to patients in China, and together with Fosun MedTech, drive continuous innovation in the radiotherapy industry.”

In the future, Fosun MedTech and Leo Cancer Care will continue to deepen their collaboration, integrating the two parties’ comprehensive strengths in technology R&D, clinical translation, market access, and localized operations, accelerating the introduction and application of the Marie® system and upright particle therapy technologies in the China market.

Together, they aim to enhance the capabilities of China’s oncology treatment ecosystem and contribute to the realization of the “Healthy China 2030” strategic vision.

Please note that the Leo Cancer Care Marie solution recently received 510(k) clearance in the United States and regulatory approval in China is planned.